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Penetrance	  and	  Expressivity	  
•  We	  do	  not	  really	  know	  the	  penetrance	  or	  
expressivity	  of	  	  pre?y	  much	  ALL	  mutaCons	  in	  
humans,	  as	  we	  have	  not	  systemaCcally	  
sequenced	  or	  karyotyped	  any	  geneCc	  alteraCon	  
in	  MILLIONS	  of	  well-­‐phenotyped	  people.	  
•  Do	  single	  mutaCons	  drive	  outcome	  
predominately,	  or	  are	  the	  results	  modified	  
substanCally	  by	  other	  mutaCons	  and/or	  
environment?	  	  Is	  there	  really	  such	  a	  thing	  as	  
geneCc	  determinism	  for	  MANY	  mutaCons?	  
Ancestry	  Ma?ers!	  -­‐	  Ogden	  Syndrome	  	  
The	  mutaCon	  is	  necessary,	  but	  we	  do	  not	  know	  if	  it	  is	  sufficient	  to	  cause	  this	  
phenotype	  in	  ANY	  geneCc	  background.	  It	  simply	  “contributes	  to”	  the	  phenotype.	  
The	  muta2on	  disrupts	  the	  N-­‐terminal	  
acetyla2on	  machinery	  (NatA)	  in	  
human	  cells.	  	  
Slide	  courtesy	  of	  Thomas	  Arnesen	  
 Simulated	  structure	  of	  S37P	  mutant	  	  
?	  
Big	  QuesCon:	  
Max	  Doerfel	   Yiyang	  Wu	  
	  hNaa10p-­‐S37P	  is	  func2onally	  
impaired	  in	  vivo	  using	  a	  yeast	  model.	  
	  
Unpublished	  data	  from	  Thomas	  Arnesen,	  do	  not	  further	  distribute.	  
=	  paCent	  samples	  prepared	  for	  N-­‐terminal	  COFRADIC	  analyses	  (but	  sCll	  
to	  be	  analyzed)	  (#8	  and	  #9)	  
=	  FFPE	  DNA	  (for	  paCent	  III.7.)	  or	  DNA	  from	  blood	  available	  (and	  for	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=	  paCent	  samples	  analyzed	  by	  N-­‐terminal	  COFRADIC	  analyses	  (#1	  to	  #5)	  
III.4.	  proband	  hemizygous,	  mutant	  (89323)	  (#1a)	  (#1b)	  
II.2.	  mother	  of	  proband,	  carrier	  (89324)	  (#2)	  
II.A.	  married-­‐in	  father	  of	  proband,	  WT(89325)	  
III.2.	  brother	  of	  proband,	  WT(90526)	  (#3)	  
III.1.	  sister	  of	  proband,	  WT	  (90527)	  (#4)	  
I.2.	  grandmother	  of	  proband,	  carrier	  (90528)	  
I.1.	  married-­‐in	  grandfather	  of	  proband,	  WT(90529)	  (#5)	  
II.7.	  aunt	  of	  proband,	  WT	  (90530)	  (#6)	  
II.3.	  aunt	  of	  proband,	  carrier	  (90531)	  
II.B.	  married-­‐in	  uncle	  of	  proband,	  WT(90532)	  (#8)	  
II.8.	  uncle	  of	  proband,	  WT(90688)	  (#9)	  
II.5.	  aunt	  of	  proband,	  carrier	  with	  deceased	  boy	  (90797)	  (#7)	  
Proteomics	  Analysis	  of	  EBV-­‐transformed	  cell	  lines	  
from	  family	  members	  
Sca)erplots	  displaying	  the	  correla4on	  of	  the	  degrees	  of	  Nα-­‐acetyla4on	  when	  
comparing	  a	  control	  (brother	  WT)(in	  this	  case	  Y-­‐axis)	  and	  the	  proband	  or	  
mother(carrier)	  (Y-­‐axis)	  N-­‐terminome	  datasets.	  The	  N-­‐termini	  displaying	  a	  
significant	  varia4on	  in	  the	  degree	  of	  Nα-­‐acetyla4on	  (see	  above)	  are	  highlighted	  
in	  orange.	  	  
















































Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
New	  Syndrome	  with	  Dysmorphology,	  Mental	  	  
RetardaCon,	  “AuCsm”,	  “ADHD”	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	   	   	   	  7	  years	  old 	   	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old 	   	   	   	  	  	  9	  years	  old 	  	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  geneCc	  tests	  negaCve,	  including	  negaCve	  for	  
Fragile	  X	  and	  many	  candidate	  genes.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  normal.	  
•  Sequenced	  whole	  genomes	  of	  Mother,	  Father	  and	  Two	  
Boys,	  using	  Complete	  Genomics,	  obtained	  data	  in	  June	  
of	  this	  year,	  i.e.	  version	  2.0	  CG	  pipeline.	  
Complete	  Genomics	  chemistry	  -­‐	  combinatorial	  











Chromosome	   PosiCon	   Reference	   Coding?	   SIFT	  Score	   Score	  <=	  0.05	   Ref/Alt	  Alleles	  
X	   47307978	   G	   YES	   0.649999976	   0	   G/T	  
X	   63444792	   C	   YES	   0	   1	   C/A	  
X	   70621541	   T	   YES	   0.009999999776	   1	   T/C	  
Variant	   Reference	   Alternate	   ClassificaCon	   Gene	  1	   Transcript	  1	   Exon	  1	   HGVS	  Coding	  1	   HGVS	  Protein	  1	  
X:47307978-­‐SNV	   G	   T	   Nonsyn	  SNV	   ZNF41	   NM_007130	   5	  c.1191C>A	   p.Asp397Glu	  
X:63444792-­‐SNV	   C	   A	   Nonsyn	  SNV	   ASB12	   NM_130388	   2	  c.739G>T	   p.Gly247Cys	  
X:70621541-­‐SNV	   T	   C	   Nonsyn	  SNV	   TAF1	   NM_004606	   25	  c.4010T>C	   p.Ile1337Thr	  
RANK	   Gene	   p-­‐value	   p-­‐value-­‐ci	   Score	   Variants	  
1	   ASB12	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   38.63056297	   chrX:63444792;38.63;C-­‐>A;G-­‐>C;0,3	  
2	   TAF1	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   34.51696816	   chrX:70621541;34.52;T-­‐>C;I-­‐>T;0,3	  
3	   ZNF41	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   32.83011803	   chrX:47307978;32.83;G-­‐>T;D-­‐>E;0,3	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1341
Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
electronically published November 18, 2003.
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
Am. J. Hum. Gen t. 73:1341–1354, 2003
1341
Mutations in the ZNF41 Gene Ar A ociated with Cognitive Deficits:
Identification of a New Candi ate for X-Linked Me tal R tardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Me zel,1 Udo Traut ann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre F yn ,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. Th 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that nu erous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-ch omosomal and the uto omal b eak-
point. In silico sequence analysis provided o indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that t e ntal
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
electronically published November 18, 2003.
Address for correspondence and reprints: Dr. Vera Kalscheuer,Max-
Planck-Institute for Molecular Genetics, Ihnestrasse 73, D-14195Berlin,
Germany. E-mail: kalscheu@molgen.mpg.de
! 2003 by The American Society of Human Genetics. All rights reserved.
0002-9297/2003/7306-0013$15.00
linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema











































































Sanger	  valida2on:	  	  ASB12	  and	  ZNF41	  muta2ons	  
The	  mutaCon	  in	  ZNF41	  may	  NOT	  be	  necessary,	  and	  it	  is	  certainly	  
NOT	  sufficient	  to	  cause	  the	  phenotype.	  
So,	  of	  course	  we	  need	  baseline	  whole	  
genome	  sequencing	  on	  everyone	  to	  at	  
least	  understand	  the	  DNA	  geneCc	  
background	  in	  each	  pedigree	  or	  clan.	  
	  
Ancestry	  Ma?ers!	  
How	  do	  we	  get	  to	  “whole”	  genome	  
sequencing	  for	  everyone?	  
•  Tool	  Building	  for	  Human	  GeneCcs	  
	  
Toward	  more	  comprehensive	  
“personal	  genomes”	  
•  Can	  we	  reliably	  detect	  a	  comprehensive,	  and	  
accurate,	  set	  of	  variants	  using	  more	  than	  one	  
pipeline,	  or	  even	  more	  than	  one	  sequencing	  
plavorm?	  
•  How	  much	  data	  is	  enough,	  and	  how	  reliable	  
and	  reproducible	  are	  variant	  calls?	  
Moving	  Exome	  and	  WGS	  into	  a	  Clinical	  
Sewng	  requires	  both	  AnalyCc	  and	  
Clinical	  Validity	  
•  AnalyCcal	  Validity:	  the	  test	  is	  accurate	  with	  
high	  sensiCvity	  and	  specificity.	  
•  Clinical	  Validity:	  Given	  an	  accurate	  test	  result,	  
what	  impact	  and/or	  outcome	  does	  this	  have	  
on	  the	  individual	  person?	  

•  ~$3000	  for	  30x	  “whole”	  genome	  as	  part	  of	  
Illumina	  Genome	  Network	  on	  a	  research	  basis	  
only,	  but	  ~$5,000	  for	  whole	  genome	  
performed	  in	  a	  CLIA	  lab	  at	  Illumina.	  
2-­‐3	  rounds	  of	  sequencing	  at	  BGI	  to	  a?ain	  
goal	  of	  >80%	  of	  target	  region	  at	  >20	  reads	  
per	  base	  pair	  
Exome Capture Statistics K24510-84060 K24510-92157-a K24510-84615 K24510-88962 
Target region (bp) 46,401,121  46,401,121  46,401,121  46,257,379  
Raw reads 138,779,950  161,898,170  156,985,870  104,423,704  
Raw data yield (Mb) 12,490  14,571  14,129  9,398  
Reads mapped to genome 110,160,277  135,603,094  135,087,576  83,942,646  
Reads mapped to target region 68,042,793  84,379,239  80,347,146  61,207,116  
Data mapped to target region (Mb) 5,337.69  6,647.18  6,280.01  4,614.47  
Mean depth of target region 115.03 143.25 135.34 99.76 
Coverage of target region (%) 0.9948  0.9947  0.9954  0.9828  
Average read length (bp) 89.91  89.92  89.95  89.75  
Fraction of target covered >=4X 98.17  98.38  98.47  94.25  
Fraction of target covered >=10X 95.18  95.90  95.97  87.90  
Fraction of target covered >=20X 90.12  91.62  91.75  80.70  
Fraction of target covered >=30X 84.98  87.42  87.67  74.69  
Capture specificity (%) 61.52  62.12  59.25  73.16  
Fraction of unique mapped bases on or near target 65.59  65.98  63.69  85.46  
Gender test result M M M F 
Depth	  of	  Coverage	  in	  15	  exomes	  >	  20	  






















Pipelines	  Used	  on	  Same	  Set	  of	  Seq	  Data	  by	  Different	  
Analysts,	  using	  Hg19	  Reference	  Genome	  
1)  BWA	  -­‐	  GATK	  (version	  1.5)	  with	  recommended	  parameters	  	  (GATK	  IndelRealigner,	  
base	  quality	  scores	  were	  re-­‐calibrated	  by	  GATK	  Table	  RecalibraCon	  tool.	  
Genotypes	  called	  by	  GATK	  UnifiedGenotyper.	  For	  SNVs	  and	  indels.	  
	  
2)  BWA	  -­‐	  SamTools	  version	  0.1.18	  to	  generate	  genotype	  calls	  	  -­‐-­‐	  The	  “mpileup”	  
command	  in	  SamTools	  was	  used	  for	  idenCfy	  SNVs	  and	  indels.	  
	  
3)  SOAP-­‐Align	  –	  SOAPsnp	  for	  SNVs–	  and	  BWA-­‐SOAPindel	  (adopts	  local	  assembly	  
based	  on	  an	  extended	  de	  Bruijn	  graph)	  for	  indels.	  
	  
4)  GNUMAP-­‐SNP	  (probabilisCc	  Pair-­‐Hidden	  Markov	  which	  effecCvely	  accounts	  for	  
uncertainty	  in	  the	  read	  calls	  as	  well	  as	  read	  mapping	  in	  an	  unbiased	  fashion),	  for	  
SNVs	  only.	  
	  
5)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format	  -­‐	  Picard	  to	  remove	  duplicates	  –	  SNVer	  ,	  for	  SNVs	  
only	  
Known	   Novel	  
All	  
Total	  mean	  overlap,	  plus	  or	  minus	  one	  standard	  devia2on,	  observed	  between	  three	  
indel	  calling	  pipelines:	  GATK,	  SOAP-­‐indel,	  and	  SAMTools.	  	  a)	  Mean	  overlap	  when	  indel	  
posiCon	  was	  the	  only	  necessary	  agreement	  criterion.	  b)	  Mean	  overlap	  when	  indel	  
posiCon,	  base	  length	  and	  base	  composiCon	  were	  the	  necessary	  agreement	  criteria.	  	  	  
Indels-­‐	  Overlap	  by	  Base	  	  
PosiCon	  only	  
Indels-­‐	  Overlap	  by	  Base	  	  
PosiCon,	  Length	  and	  ComposiCon	  
INDELS	  
•  How	  reliable	  are	  variants	  that	  are	  uniquely	  
called	  by	  individual	  pipelines?	  
•  Are	  some	  pipelines	  be?er	  at	  detecCng	  rare,	  or	  
novel	  variants	  than	  others?	  
Cross	  validaCon	  using	  orthogonal	  
sequencing	  technology	  







What	  is	  the	  “True”	  Personal	  Genome?	  
35653	   19407	  17322	  
2666	  
18331	   2085	  
915	  
50.5%	   32.2%	   17.3%	  
48.6%	   45.9%	   5.5%	  
Known	   Novel	  
All	  












































Personal	  genome	  “K8101”	  
All	  
Higher	  ValidaCon	  of	  SNVs	  with	  the	  
BWA-­‐GATK	  pipeline	  
•  Reveals	  higher	  validaCon	  rate	  of	  unique-­‐to-­‐
pipeline	  variants,	  as	  well	  as	  uniquely	  
discovered	  novel	  variants,	  for	  the	  variants	  
called	  by	  BWA-­‐GATK,	  in	  comparison	  to	  the	  
other	  4	  pipelines	  (including	  SOAP).	  
Much	  Higher	  ValidaCon	  of	  the	  Concordantly	  
Called	  Variants	  (by	  the	  CG	  data)	  
ValidaCng	  Indels	  with	  Complete	  
Genomics	  Data	  for	  the	  3	  pipelines	  
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked.	  





•  Ancestry,	  i.e.	  geneCc	  background,	  ma?ers!	  
•  We	  need	  to	  sequence	  whole	  genomes	  of	  large	  
pedigrees,	  and	  then	  construct	  super-­‐family	  
structures,	  starCng	  in	  Utah.	  
•  CollecCvely,	  we	  need	  to	  improve	  the	  accuracy	  
of	  “whole”	  genomes,	  and	  also	  enable	  the	  
sharing	  of	  genotype	  and	  phenotype	  data	  
broadly,	  among	  researchers,	  the	  research	  





Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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